Yissum - Research Development Company of the Hebrew University

Novel Anti-hyperglycemic Drugs

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Novel pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. These novel pentose derivatives have beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising them.
Keywords: diabetes

Project ID : 12-2006-177

Description of the technology

Novel pentose derivatives for treating hyperglycemia


Diabetes drugs, hyperglycemia

Patent Status

Patent granted in US and pending in EU

Development Stage

Proof of concept in animal models, acute toxicology performed

Market Size

Global diabetes drugs treatment market was valued at $15 billion in 2005


Existing anti-hyperglycemic drugs that ameliorate insulin secretion and action have a relatively high rate of failure.

  • There is an intensive worldwide effort to develop a new generation of anti-hyperglycemic drugs that mimic insulin action even in the total absence of insulin.
  • This novel approach is based on the discovery that some pentoses and their derivatives augment glucose transport in skeletal muscle cells in a non-insulin-dependent manner.

Our Innovation

These potential antihyperglycemic drugs may reduce high blood glucose levels in Type-2 diabetic subjects by augmenting the rate of peripheral glucose disposal in insulin sensitive tissues (i.e., skeletal muscles).

Key Features

  • Increases rate of cellular glucose transport and utilization
  • Improves peripheral glucose disposal
  • Treats daily glucose fluctuations
  • Reduces dosage of anti-diabetic medication needed for diabetes treatment

Development Milestones

  • Pharmacokinetic studies of the drug delivery system using larger number of volunteers
  • Toxicology
  • In vitro and in vivo evaluation of current and planned formulations of the prototype compounds

The Opportunity

  • Diabetes affects over 180 million people worldwide and the market is growing at three times the rate of population growth. Poor control of blood sugar results in severe long-term complications such as kidney failure, nerve damage, blindness, amputation and cardiovascular disease.
  • In recent years, there has been a change in the treatment of hyperglycemia in the United States away from monotherapy with oral antihyperglycemic drugs toward combination therapies to improve glycemic control and reduce the risk of hypoglycemic symptoms in treated individuals.

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Shlomo Sasson
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.